WGS Analysis of COVID-19 Positive Patients

Completed

• Conditions: COVID-19; Coronavirus Infection

• Registration Number: NCT04353401
• Lead Sponsor: Vanda Pharmaceuticals

Brief Summary

We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-04-15
• Study First Submitted QC: 2020-04-15
• Study First Posted: 2020-04-20
• Study Start: 2020-08-03
• Primary Completion: 2022-03-09
• Study Completion: 2022-03-09
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-20
• Last Update Posted: 2024-03-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 79

Inclusion Criteria

• Ability and acceptance to provide written informed consent and fluent in English.
• Men or women between 18-100+ years, inclusive.
• Willing to comply with study procedures.
• SARS-CoV-2 positive test result as confirmed by a RT-PCR assay with a sputum or nasopharyngeal sample (either done prior to or at the screening visit).

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Associations with severity and outcomes	3 months	Clinical associations with human and viral genetics

Trial Locations

Locations (1)

Vanda Investigational Site; 🇺🇸 Cleveland, Ohio, United States